OBJECTIVES: quality of life (QOL) is an important outcome in lung patient (LC) treated by chemotherapy. Alopecia may be an important part of this QOL but in fact very few data’s are availablethe aim of this study is to assess, in patients treated by chemotherapy, the impact of alopecia. METHODS: This prospective, single centre study, use a willingness to pay method. Advanced LC patients were asked first to assess the impact of alopecia in second line chemotherapy setting from an analogical visual scale (from 0 : no impact to 10 major impact); then they participated, in a face to face interview, at the presentation of a hypothetical scenario giving the choice between 2 chemotherapies with the same efficacy, the same pattern of administration (every 3 weeks, in day care hospital) and the same tolerability except for the risk of alopecia : 5% for the product A and 40% for the product B and were asked for their willingness to pay for product A. RESULTS: Sixty-four patients had been enrolled (59%, age : 60,8 ± 10,3 y, married 58%). In analogical visual scale, the impact of alopecia were assessed at 4,1 ± 3,4. Patients were willing to pay, for a 3-week chemotherapy cycle, a median amount of €130,4 ± 151.9 (median 62.5) to receive the product with the lower rate of alopecia. But 27 (42.2%) are not ready to pay anything. The patients no willing to pay are more often men (p<0.001), no married (p<0,03), have low income (p<0,001) and hairless before treatment (p<0.001). Correlation between the results of the analogical visual scale and the willingness to pay is good. CONCLUSIONS: a limit of this study is the context of the French health system (universal health coverage) with no payment by the patient for chemotherapy treatment than the scenario tested is really hypothetical and may under or over estimated the real willingness to pay of the participants. Prospective international studies are needed to confirm these preliminaries results.